Webinar | Intra-Aortic Balloon Pumps (IABP)| December 22, 2015

Webinar: Hemodynamics of Counterpulsation

This webinar is sponsored by Maquet

IABP

The webinar "Hemodynamics of Counterpulsation" explained how the intra-aortic balloon pump (IABP) can increase diastolic aortic pressure and augment coronary blood flow and reduce aortic and left ventricular systolic pressure or afterload. This education offering provides a review of the physiologic benefits, evaluation of patient response, discusses how patients may derive the most benefit and offers practical technical components to optimize IABP therapy.


The live webinar was Jan. 28, 2016, but a recorded version is available on demand.  
Register for the on demand webinar


Statement of Purpose/Need: 

The Intra-aortic balloon pump (IABP) has been the first-line choice for mechanical circulatory support around the world due to its clinical efficacy, safety profile across a broad range of patient care scenarios, and low cost. IABP therapy is the most widely used nondurable mechanical circulatory support device (MCS), with more than 160,000 IAB catheters placed globally per a year. The primary goals of the IABP are to (1) increase diastolic aortic pressure and augment coronary blood flow, and (2) reduce aortic and left ventricular systolic pressure or afterload. This education offering will provide a review of the physiologic benefits, evaluate patient response, discuss what patients may derive the most benefit and practical technical components to optimize IABP therapy.


After completing the webinar, the participant should be able to::


• Assess the physiologic effects of Intra-aortic balloon counterpulsation (IABP) therapy

• Understand the clinical utility of IAB use

• Describe the factors that effect IAB catheter performance and benefits of larger-capacity IAB catheters


Speaker:



Atman P. Shah 

Associate Professor of Medicine 

Clinical Director, Section of Cardiology 

Co-Director, Cardiac Catheterization Laboratory


Atman P. Shah, M.D., is an interventional cardiologist at the University of Chicago. Shah's research efforts focus on improving survival rates in patients who have experienced a cardiac arrest or an acute myocardial infarction (heart attack). Additionally, he studies new therapies that can help save heart muscle during a heart attack. Shah is the primary investigator on a number of large multicenter clinical trials investigating novel medications and devices designed to improve the quality of life in patients with coronary artery and structural heart disease. Shah has authored six book chapters and more than 50 abstracts and publications. A dedicated educator, he trains medical students, residents and fellows. He is the recipient of several honors and awards for clinical service, leadership and teaching.


About Maquet Medical Systems

Since 1838, the Maquet brand has been synonymous with high-quality products for patient-focused care. Maquet is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. Cardiovascular specialties include intra-aortic balloon counterpulsation therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation. Maquet continuously strives to develop innovative technologies that enhance clinical expertise and improve healthcare economics, while also enabling medical professionals to achieve the best possible outcomes for all patients.


For more information please visit www.maquet.com



Register for the on demand webinar


Related Content

Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
TherOx Gains FDA PMA Approval for SSO2 Therapy System
Technology | Cath Lab| September 29, 2017
September 29, 2017 — TherOx Inc. announced that the U.S.
Overlay Init